Elanco Animal Health Inc
ELAN13.895USD
+0.105+0.76%
Market hours （ET）Quotes delayed by 15 min
6.90BMarket Cap
18.49P/E TTM
More Details of Elanco Animal Health Inc Company
Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Company Info
Ticker SymbolELAN
Company nameElanco Animal Health Inc
IPO dateSep 20, 2018
CEOMr. Jeffrey N. (Jeff) Simmons
Number of employees9000
Security typeOrdinary Share
Fiscal year-endSep 20
Address2500 Innovation Way N
CityGREENFIELD
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code46140-9163
Phone18773526261
Websitehttps://www.elanco.com/
Ticker SymbolELAN
IPO dateSep 20, 2018
CEOMr. Jeffrey N. (Jeff) Simmons
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
150.03K
+26.80%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
99.26K
--
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
80.96K
--
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
79.40K
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Independent Director
Independent Director
74.50K
--
Mr. James Meer
Mr. James Meer
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
62.55K
-1.82%
Ms. Shiv O'Neill
Ms. Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.92K
+100.82%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
150.03K
+26.80%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
99.26K
--
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
80.96K
--
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Pet Health
635.00M
53.23%
Farm Animal
546.00M
45.77%
Contract Manufacturing
12.00M
1.01%
By RegionUSD
Name
Revenue
Proportion
International
639.00M
53.56%
United States
554.00M
46.44%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Pet Health
635.00M
53.23%
Farm Animal
546.00M
45.77%
Contract Manufacturing
12.00M
1.01%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
16.70%
PRIMECAP Management Company
10.11%
The Vanguard Group, Inc.
9.69%
Fidelity Management & Research Company LLC
7.71%
Black Creek Investment Management, Inc.
4.44%
Other
51.35%
Shareholders
Shareholders
Proportion
Dodge & Cox
16.70%
PRIMECAP Management Company
10.11%
The Vanguard Group, Inc.
9.69%
Fidelity Management & Research Company LLC
7.71%
Black Creek Investment Management, Inc.
4.44%
Other
51.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
63.16%
Investment Advisor/Hedge Fund
32.92%
Hedge Fund
3.35%
Individual Investor
1.08%
Research Firm
1.01%
Sovereign Wealth Fund
0.79%
Pension Fund
0.77%
Bank and Trust
0.44%
Family Office
0.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
879
514.22M
103.54%
-39.32M
2025Q1
974
511.32M
102.96%
-71.50M
2024Q4
996
503.77M
101.85%
-80.73M
2024Q3
1000
494.48M
100.04%
-96.31M
2024Q2
1034
494.94M
100.16%
-92.98M
2024Q1
1051
494.01M
100.22%
-99.13M
2023Q4
1048
492.96M
100.04%
-103.67M
2023Q3
1055
493.54M
100.18%
-93.98M
2023Q2
1067
490.17M
99.54%
-75.35M
2023Q1
1071
498.03M
101.25%
-46.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
82.92M
16.7%
-260.08K
-0.31%
Mar 31, 2025
PRIMECAP Management Company
50.22M
10.11%
-941.63K
-1.84%
Mar 31, 2025
The Vanguard Group, Inc.
48.14M
9.69%
-437.73K
-0.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
38.30M
7.71%
+9.79M
+34.35%
Mar 31, 2025
Black Creek Investment Management, Inc.
22.04M
4.44%
+1.61M
+7.87%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
20.46M
4.12%
+2.56M
+14.32%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.06M
4.04%
-618.85K
-2.99%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
15.98M
3.22%
+292.65K
+1.87%
Mar 31, 2025
Fidelity Institutional Asset Management
15.55M
3.13%
+3.83M
+32.70%
Mar 31, 2025
Shapiro Capital Management LLC
12.33M
2.48%
-24.38K
-0.20%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
3.83%
iShares U.S. Pharmaceuticals ETF
3.57%
First Trust Health Care Alphadex Fund
3.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.72%
First Trust NASDAQ Pharmaceuticals ETF
2.36%
Brandes US Small-Mid Cap Value ETF
2.14%
VanEck Agribusiness ETF
1.51%
First Trust Mid Cap Value AlphaDEX Fund
0.98%
Global X Adaptive US Factor ETF
0.72%
Federated Hermes MDT Large Cap Value ETF
0.7%
View more
SPDR S&P Pharmaceuticals ETF
Proportion3.83%
iShares U.S. Pharmaceuticals ETF
Proportion3.57%
First Trust Health Care Alphadex Fund
Proportion3.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.72%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.36%
Brandes US Small-Mid Cap Value ETF
Proportion2.14%
VanEck Agribusiness ETF
Proportion1.51%
First Trust Mid Cap Value AlphaDEX Fund
Proportion0.98%
Global X Adaptive US Factor ETF
Proportion0.72%
Federated Hermes MDT Large Cap Value ETF
Proportion0.7%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
